Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study

Cornelis A van den Bogert,1,2,3 Patrick C Souverein,1 Cecile T M Brekelmans,2 Susan W J Janssen,3 Manon van Hunnik,1,3 Gerard H Koëter,2 Hubertus G M Leufkens,1 Lex M Bouter4

ABSTRACT

Introduction: Responsible conduct of research implies that results of clinical trials should be completely and adequately reported. This article describes the design of a cohort study that aims to investigate the occurrence and the determinants of selective reporting in an inception cohort of all clinical drug trials that were reviewed by the Dutch Institutional Review Boards (IRBs) in 2007. It also describes the characteristics of the study cohort.

Methods and analysis: In 2007, Dutch IRBs reviewed 622 clinical drug trials. For each trial, we assessed the stages of progress. We discriminated five intermediate stages and five definite stages. Intermediate stages of progress are: approved by an IRB; started inclusion; completed as planned; terminated early; published as article. The definite stages of progress are: rejected by an IRB; never started inclusion; not published as article; completely and multivariate Cox regression models to identify trial characteristics associated with non-publication. We will identify seven trial-specific discrepancy items, including the objectives, inclusion and exclusion criteria, end points, sample size, additional analyses, type of population analysis and sponsor acknowledgement. The percentage of trials with discrepancies between the protocol and the publication will be scored. We will investigate the association between trial characteristics and the occurrence of discrepancies.

Ethics and dissemination: No IRB-approval is required for this study. Access to confidential research protocols was provided by the Central Committee on Research Involving Human Subjects. We plan to finish data collection in June 2015, and expect to complete data cleaning, analysis and manuscript preparation within the next 3 months. Hence, a first draft of an article containing the results is expected before the end of October 2015.

INTRODUCTION

Responsible conduct of clinical research implies that results of clinical trials should be completely and adequately reported.1,2 However, a significant part of clinical trial results is never reported: on average, only 50% of clinical trials that are started are published in the scientific literature.3–20 As published reporting gives the nature or direction of the trial conclusions, incomplete reporting may result in publication bias.8,9,19,21–24 For example, if negative findings are more often not published than positive findings, the overall evidence synthesis will be biased, which can harm patients.25–27

Publishing negative results is sometimes judged irrelevant or uninteresting by the investigator, the journal editor or the sponsor of the trial.28 Negative trials, however, add valuable information to the body of evidence on the effects of the interventions studied. Moreover, publishing negative findings can
Selecting those reporting of trial results comes in two forms. First, selective reporting can mean that the trial at issue is never published in the scientific literature (non-publication). This can be evaluated by searching for publications on trials included in an inception cohort, for example, using information from a trial register. Second, selective reporting may indicate that a trial is published in the scientific literature with changes, omissions, or additions of study aspects or findings (selective publication). The second form of selective reporting is more subtle and can only be verified by comparing published reports to the full original study protocol.

Non-publication rates of 10–88% have been reported in the literature. Selective publication was identified by studying discrepancies between the protocol and publication in reporting end points, sample size, statistical methods and subgroup analysis. That non-publication and selective publication can lead to patient harm was also shown in clinical trials with drugs intended for marketing authorisation. Some new drugs had to be withdrawn from the market after additional data was revealed showing harmful effects. For example, clinical data on the new anti-inflammatory drug rofecoxib were neither published in the literature, nor revealed to the regulators. Other examples of non-publication and selective publication potentially resulting in patient harm include the antihypertensive drug reboxetine, and the antiarrhythmic drug lorcainide. The negative media attention about these and other drug trials has caused a decrease of the public’s trust in the pharmaceutical industry and medical research.

That non-publication and selective publication can lead to patient harm was also shown in clinical trials with drugs intended for marketing authorisation. Some new drugs had to be withdrawn from the market after additional data was revealed showing harmful effects. For example, clinical data on the new anti-inflammatory drug rofecoxib were neither published in the literature, nor revealed to the regulators. Other examples of non-publication and selective publication potentially resulting in patient harm include the antihypertensive drug reboxetine, and the antiarrhythmic drug lorcainide. The negative media attention about these and other drug trials has caused a decrease of the public’s trust in the pharmaceutical industry and medical research.

Also, we identified the characteristics of these trials (see online supplementary table S1). The used source was the General Assessment and Registration (GAR) form. This is a standard obligatory form that investigators submit to the IRB. For 194 trials, multiple therapeutic areas were indicated. Two investigators (CvdB and CTMB) independently examined whether these trials could be reclassified to a single therapeutic area and classified the combination trials as one therapeutic area. Differences were solved by consensus after involving a third investigator (GHK). To reduce the large number of different therapeutic areas, we reclassified the variable to the International Classification of Diseases, V.10. This reclassification retained 11 therapeutic areas and 1 ‘other’ category.

From the trials included, we will extract data on the stages of progress, non-publication and selective publication. In addition to the public data sources and original trial protocols, we plan to send out a questionnaire to the investigators. An overview of the variables we plan to extract is presented in the data extraction form (see online supplementary table S2).

**Stages of progress**

For the 622 trials in the inception cohort, we will determine the various stages of progress (figure 1). For each clinical drug trial, we will discriminate 10 stages of progress. Of these, five are intermediate (meaning that further action is observed or possible), and five are definite (meaning that no further action is observed or possible). We named the stages of progress according to the flow of the cohort, shown in figure 1. The intermediate stages of progress are: B1 approved by IRB; C1 started inclusion; D1 completed as planned; D2 terminated early; E1 published as article. The definite stages of progress are: B2 rejected by IRB; C2 Never started inclusion; E2 Not published as article; F1 completely reported;
F2 selectively reported. We primarily aim to investigate the publication-related stages of progress E1, E2, F1 and F2. However, to understand why these stages of progress are not reached, we also determine the other stages of progress. The stage of progress F2 (selectively reported) is definite for the end of our data collection; later publications can still fill the remaining gaps by moving trials to F1 (completely reported).

Non-publication
We search for publications on the trial results in the scientific literature using a standardised algorithm (figure 2). A publication is defined as a peer-reviewed article containing at least methods and results. All reports not fulfilling this publication (e.g., results reported in registries, conference abstracts containing results, trial summaries on sponsor websites containing methods and results) will be also collected. Peer-reviewed publication is in our opinion the golden standard for reporting clinical research, but trial results can be reported by other means (e.g., registries, sponsor websites, conference abstracts). Using only peer-reviewed articles as end point for non-publication is in line with the majority of other research.\(^4^7\) If we identify more than one publication of trial results, we classify the publication as either primary (i.e., containing the overall results and conclusions) or secondary (i.e., interim, post hoc, subgroup or other analysis). In general, we assume that this will be clearly stated in the publications.\(^4^2\) Other information collected includes the full-text of the article, the journal and the first date of publication (e.g., advance online publication). We have completed this part of the publication search in March 2015.

We will also collect the end of trial date and information about (early) termination of the trial. We define the end of trial date as the date of the last visit of the last patient undergoing the trial.\(^5^0\) A trial is terminated early if either the inclusion or the follow-up is terminated earlier than foreseen in the research protocol. Since early termination is an intermediate stage of progress of a trial, we include early termination as a potential determinant for the end points studied. In addition, prospective registration on clinicaltrials.gov will be examined as a potential determinant (table 1). We define prospective registration as registration of the trial before the first patient is recruited;\(^1\) The data field ‘first received’ on clinicaltrials.gov will be used as the date of registration.

To validate the used publication search algorithm, two investigators independently searched for publications using the algorithm, using a random selection of 30 trials of the cohort. The two searches identified no differences.

Figure 1  Overview of stages of progress of the 2007 inception cohort of clinical drug trials in the Netherlands. The numbers in the boxes indicate the numbers of trials that succeeded to the specific stages of progress. From B1, C1, D1, E1 to F1 is the ‘perfect’ flow of a trial in the cohort, meaning that all aspects took place according to the application. The sum of the boxes B2, C2, E2 F1 and F2, which are the five final stages of progress, will be 622.

A. Inception cohort: clinical drug trials reviewed by a Dutch IRB in 2007  
\(N = 622\)

- B1. Approved by Dutch IRB  
  \(N = 603\)
- B2. Rejected by Dutch IRB  
  \(N = 19\)
- C1. Started inclusion
- C2. Never started inclusion
- D1. Completed as planned
- D2. Early terminated
- E1. Published as article
- E2. Not published as article
- F1. Completely reported
- F2. Selectively reported

Reasons for non-publication
Discrepancies: Types Determinants


Open Access
We checked the external validity of the algorithm by comparing the results to a search algorithm used for another study, provided by the investigators. This comparison showed no differences, which suggested that the construct validity of our algorithm was adequate.

In addition, we will send questionnaires to the main investigators of the research divisions or hospital departments that conducted the trials. We will specifically ask the investigators to confirm or rectify our information about which stage of progress the trial reached according to our findings. For the non-published trials, we ask for the reasons that the trial was not published (box 1) and whether the results of the trial were reported in alternative ways, such as on clinicaltrials.gov. When the investigator does not respond to the mailed questionnaire, we will try to engage the investigator by telephone contact. In case we are unable to contact the investigator, we will contact the sponsor of the trial.

The various stages of progress of the trial in the flowchart will be updated according to the results of the questionnaire. In case neither the investigator nor the sponsor could be reached, the stages of progress remain unchanged. We assume that if a trial was incorrectly placed in the stage of progress boxes C2, D2, or E2, the investigator or sponsor would have responded. If we are unable to find any information on whether a trial started inclusion, ended or was published, we will exclude the trial for subsequent analysis. After showing construct validity, the publication search was performed by two authors (CAvdB and MvH), double-checked by

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Planned analyses, end points and determinants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Determinants</strong></td>
<td><strong>End point</strong></td>
</tr>
<tr>
<td>Analysis of non-publication</td>
<td>Analysis of selective publication*</td>
</tr>
<tr>
<td>Analysis of selective publication*</td>
<td>Trial characteristics+early termination+prospective registration on clinicaltrials.gov</td>
</tr>
<tr>
<td>Discrepancies between protocol and publication*</td>
<td>Discrepancies between protocol and publication</td>
</tr>
<tr>
<td>Direction of publication conclusions‡</td>
<td></td>
</tr>
</tbody>
</table>

*Only among randomised trials.
†Only among published trials.

---

Figure 2 Publication search algorithm. EudraCT, European Union Drug Regulating Authorities Clinical Trials: obligatory registration database for clinical drug trials carried out in the European Union.
the questionnaire to the investigators. To assess the likelihood of bias, we will investigate whether the characteristics of included cases differ from excluded cases.

Selective publication

Among the trial protocols that resulted in a publication, we will further investigate selective publication. We include only peer-reviewed articles for the discrepancy analysis because other reports contain too little detail to investigate discrepancies with the trial protocol. Selective publication can be measured by identifying discrepancies between protocol and publication. Discrepancies between protocol and publication are indications of selective publication, which may lead to reporting bias. The degree of the risk of reporting bias depends on the association of discrepancies with the direction of trial conclusions. Therefore, among the trials with a randomised design, we will also assess the direction of publication conclusions and investigate whether the direction of publication conclusions is associated with discrepancies between protocol and publication.

We define discrepancies between protocol and primary publication as additions, omissions or changes in prespecified discrepancy-items. To identify discrepancies systematically, we developed an extraction form containing relevant items. We used items from common protocol and publication guidelines like SPIRIT and CONSORT to compel a list with trial items that should be reported. From that list, we selected seven items in which we expected selective reporting (see online supplementary table S2). The seven discrepancy items include: (1) objectives, (2) inclusion and exclusion criteria, (3) end points, (4) sample size, (5) additional analyses, (6) type of population analysis and (7) sponsor acknowledgement. We will extract these items both from the protocols and the publications. Subsequently, we will compare the extracted data of the protocol to the publications. With regard to discrepancies in the objectives and end points, we will distinguish between discrepancies in the primary and in the secondary objectives, and end points. With regard to discrepancies in the inclusion and exclusion criteria, we will only consider an objective change as discrepancy because inclusion and exclusion criteria are often not fully reported in publications due to the limited availability of space. We will operationalise discrepancies in the planned versus included sample size as the ratio of sample size achieved divided by sample size planned. With regard to discrepancies in the type of population analysis, we will assess whether an intention-to-treat or per-protocol analysis was planned and used accordingly. We will also indicate when there was a lack of information in the protocol and/or in the publication to assess a discrepancy.

In case we identify multiple publications of one trial protocol, we will include the primary publication in the discrepancy assessment. In addition, if a secondary publication contains any analyses that were not described in the study protocol and this was not stated in the publication, we classify that as an additional discrepancy.

The discrepancy assessment was developed by one author (CAvdB), and will be tested for construct validity by a second author (PCS) by performing an independent discrepancy assessment of a random selection of 10% of the published trials. Remaining differences will be solved by discussing these with two other authors (CTMB and SWJJ). The remaining trials will then be assessed by one author (CAvdB), with a randomly selected double-check of 20 of the published trials by a second author (PCS). Uncertainties will be solved by a discussion involving two other authors (CTMB and SWJJ).

Among the trials with a randomised design, we will classify the direction of publication conclusions as either positive or negative. This classification is included to investigate whether discrepancies are associated with the direction of the conclusions (and the interpretation) that the authors draw in the discussion sections of the publications. If trials with a positive conclusion have more discrepancies than trials with a negative conclusion, this may mean that discrepancies are used to spin trial conclusions towards a positive direction. Two independent investigators (CAvdB and PCS) will independently classify the trials, and solve differences by consensus.

Data analysis

According to the objectives of the study, we will analyse three end points (table 1): non-publication, discrepancies between the protocol and the publication as a proxy for selective publication and the direction of publication conclusions.

Non-publication

In a survival analysis of the non-publication rate, only trials that started inclusion will be analysed (box C1 of figure 1). The end point used is non-publication as peer-reviewed article, according to the definition provided above. The trial end date marks the start of follow-up (ie, the date the trial transits to the stage of progress D1 or D2, figure 1). We chose this date instead of the date of IRB approval because the trials in the cohort might differ in time span. This time span may depend, for example, on the phase of the trial and the number of participants to be recruited. In case of multiple publications of one trial protocol, we use the publication date of the primary publication.

We assume that all trials that started including participants are eligible for publication. Thus, the population of the

Box 1 Reasons for not publishing results, to be obtained from the questionnaire (for unpublished completed trials in cohort)

- Manuscript is in preparation/under review
- Results were not interesting enough to publish
- Journal rejected the manuscript
- Sponsor decided not to publish without providing a reason
- Other

헤리시FromArray

non-publication survival analysis includes all trials that started inclusion (box C1, figure 1). Trials that never started inclusion are excluded from this analysis.

To identify characteristics that are associated with (non-)publication, we perform Cox regression analysis to estimate the strength of the association between characteristics and publication status, expressed as HRs and 95% CIs. Since trials of oncolytic drugs are different with respect to the disease severity compared to most trials in other therapeutic areas (which may affect publication), a stratified analysis will be conducted as well. In addition, we will tabulate reasons for non-publication. Finally, we will describe the means of publication by other means than by the definition of publication. By doing so, we will identify the subset of trials with no results reported at all (not as peer-reviewed article and not by any other means).

Selective publication

For each of the seven discrepancy-items, we calculate the proportion of trials with the discrepancy. We investigate the association between characteristics and discrepancies for each item ($\chi^2$ test) and for the total discrepancy summary score (paired t test). We will use multivariable logistic (individual discrepancies) and linear (total discrepancy score) regression models to estimate the strength of the association of characteristics and publication status, expressed as ORs and 95% CIs. Among the trials with a randomised design, we investigate whether the discrepancies are associated with the direction of the publication conclusions using identical bivariate and multivariate analyses. Data analysis will be performed by two authors (CAvdB and PCS), and double-checked by all other authors.

By measuring non-publication and selective publication, the study will identify the extent of research under-reporting waste in a cohort of clinical trials in the Netherlands. To increase the value derived from clinical trials, transparency from protocol to the public is needed. Our study will provide this on a national level and may elucidate areas for improvement. Ultimately, this study may contribute to evidence-based medicine by improving the unbiased reporting rates of clinical drug trials. This may increase the overall trust in research on drugs and the willingness of participants to enrol in clinical drug trials.

ETHICS AND DISSEMINATION

As our study involves no human participants, no IRB-approval is required. Access to confidential research protocols was provided by the Central Committee on Research Involving Human Subjects. We plan to finish data collection in June 2015, and expect to complete data cleaning, analysis and manuscript preparation within the next 3 months. Hence, a first draft of an article containing the results is expected before the end of October 2015.

REFERENCES


40. Lexchin J. Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of alternative medications. Sci Eng Ethics 2012;18:247–61.


Occurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort study

Cornelis A van den Bogert, Patrick C Souverein, Cecile T M Brekelmans, Susan W J Janssen, Manon van Hunnik, Gerard H Koëter, Hubertus G M Leufkens and Lex M Bouter

BMJ Open 2015 5:
doi: 10.1136/bmjopen-2015-007827

Updated information and services can be found at:
http://bmjopen.bmj.com/content/5/7/e007827

These include:

Supplementary Material
Supplementary material can be found at:
http://bmjopen.bmj.com/content/suppl/2015/07/07/bmjopen-2015-007827.DC1.html

References
This article cites 46 articles, 17 of which you can access for free at:
http://bmjopen.bmj.com/content/5/7/e007827#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Ethics (39)  
Evidence based practice (336)  
Medical publishing and peer review (37)  
Public health (1070)  

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/